Table 1. Comparison of All-Sites Cancer Cases Before and During the COVID-19 Pandemic, USCS Public Use Database.
| Characteristic | No. (%) | |
|---|---|---|
| Before COVID-19 pandemica | During COVID-19 pandemicb | |
| Total cases | 3 800 931 | 1 302 313 |
| Included casesc | 3 787 834 (99.7) | 1 297 874 (99.7) |
| Cases missing monthd | 13 097 (0.3) | 4439 (0.3) |
| Sex | ||
| Female | 1 859 253 (49.1) | 640 131 (49.3) |
| Male | 1 928 581 (50.9) | 657 743 (50.7) |
| Age, y | ||
| <65 | 1 604 318 (42.4) | 540 768 (41.7) |
| ≥65 | 2 183 516 (57.6) | 757 106 (58.3) |
| Race | ||
| Black | 425 189 (11.2) | 144 743 (11.2) |
| White | 3 132 990 (82.7) | 1 066 556 (82.2) |
| Othere | 229 655 (6.1) | 86 575 (6.7) |
| Urbanicity | ||
| Metropolitan | 3 094 333 (81.7) | 1 059 222 (81.6) |
| Nonmetropolitan | 599 370 (15.8) | 205 297 (15.8) |
| Unknown | 94 131 (2.5) | 33 355 (2.6) |
| Cancer stage | ||
| Early | 1 697 184 (44.8) | 559 810 (43.1) |
| Late | 1 663 958 (43.9) | 590 829 (45.5) |
| Unknown | 426 692 (11.3) | 147 235 (11.3) |
| State-level COVID-19 response | ||
| More restrictive | 2 204 667 (58.2) | 751 374 (57.9) |
| Less restrictive | 1 583 167 (41.8) | 546 500 (42.1) |
Abbreviation: USCS, US Cancer Statistics.
a
From January 1, 2018, through February 29, 2020; these cases were used to build autoregressive integrated moving average models.
b
From March 1 through December 31, 2020.
c
Denominator used for calculating subgroup percentages.
d
Cases missing month of cancer diagnosis in 2020 were assigned to the pandemic study period.
e
Included American Indian, Alaska Native, Asian, Pacific Islander, and unknown.